Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection

被引：0
|
作者：
Mark A. Frye
Charles B. Nemeroff
机构：
[1] Mayo Clinic Alix School of Medicine,Department of Psychiatry & Psychology, Mayo Clinic
[2] University of Texas at Austin Dell Medical School,Department of Psychiatry & Behavioral Sciences
来源：
Neuropsychopharmacology | 2024年 / 49卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：770 / 771
页数：1
相关论文
共 50 条
  • [41] Pharmacogenetic testing for selection of antidepressant treatment
    Menke, A.
    PHARMACOPSYCHIATRY, 2024, 57 (02) : 89 - 89
  • [42] Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway Approach
    Farrell, James J.
    Moughan, Jennifer
    Wong, Jonathan L.
    Regine, William F.
    Scaefer, Paul
    Benson, Al B.
    Macdonald, John S.
    Liu, Xiyong
    Yen, Yun
    Lai, Raymond
    Zheng, Zhong
    Bepler, Gerold
    Guha, Chandan
    Elsaleh, Hany
    GASTROENTEROLOGY, 2012, 142 (05) : S113 - S113
  • [43] Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial
    Xu, Lei
    Li, Liyin
    Wang, Qiutang
    Pan, Bing
    Zheng, Leilei
    Lin, Zheng
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 359 : 117 - 124
  • [44] Assessing the impact of pre-test education on patient knowledge, perceptions, and expectations of pharmacogenomic testing to guide antidepressant use
    Sloat, Nicholette T.
    Yashar, Beverly M.
    Ellingrod, Vicki L.
    Ward, Kristen M.
    JOURNAL OF GENETIC COUNSELING, 2022, 31 (06) : 1373 - 1382
  • [45] Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment
    Kotur, Nikola
    Lazic, Jelena
    Ristivojevic, Bojan
    Stankovic, Biljana
    Gasic, Vladimir
    Dokmanovic, Lidija
    Krstovski, Nada
    Milosevic, Goran
    Janic, Dragana
    Zukic, Branka
    Pavlovic, Sonja
    GENES, 2020, 11 (04)
  • [46] Does Pharmacogenomic Testing Meaningfully Improve Antidepressant Treatment Outcomes When Looking Only at Patients Taking Phase I Hepatically Metabolized Drugs? A Little
    Goldberg, Joseph F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2019, 80 (06)
  • [47] DEFINING A CLINICAL VALIDITY FRAMEWORK FOR PHARMACOGENOMIC BIOMARKERS OF IVF TREATMENT RESPONSE AND OUTCOMES.
    Parfitt, David-Emlyn
    Clementi, Caterina
    Cohn, Karen Hunter
    Mohebbi, Lili
    Augello, Frank S.
    Beim, Piraye Yurttas
    FERTILITY AND STERILITY, 2019, 112 (03) : E260 - E260
  • [48] Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia
    Joseph L McClay
    Daniel E Adkins
    Karolina Åberg
    Jozsef Bukszár
    Amit N Khachane
    Richard S E Keefe
    Diana O Perkins
    Joseph P McEvoy
    T Scott Stroup
    Robert E Vann
    Patrick M Beardsley
    Jeffrey A Lieberman
    Patrick F Sullivan
    Edwin J C G van den Oord
    Neuropsychopharmacology, 2011, 36 : 616 - 626
  • [49] Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia
    McClay, Joseph L.
    Adkins, Daniel E.
    Aberg, Karolina
    Bukszar, Jozsef
    Khachane, Amit N.
    Keefe, Richard S. E.
    Perkins, Diana O.
    McEvoy, Joseph P.
    Stroup, T. Scott
    Vann, Robert E.
    Beardsley, Patrick M.
    Lieberman, Jeffrey A.
    Sullivan, Patrick F.
    van den Oord, Edwin J. C. G.
    NEUROPSYCHOPHARMACOLOGY, 2011, 36 (03) : 616 - 626
  • [50] Implementing preemptive, multigene, pharmacogenomic testing in the inpatient setting: Preliminary results from a small, rural facility
    Cole, Jennifer L.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2024, 7 (03): : 207 - 214
12345